11月8日,生物科技公司库拉肿瘤公司(KURA)盘中股价大跌5.63%,引发市场关注。据相关新闻报道,该公司当日公布的2024年第三季度财报数据一直让投资者失望。
具体来看,库拉肿瘤第三季度营收为零,低于市场预期,且亏损幅度扩大至5440万美元,每股亏损0.63美元,同比去年同期亏损0.50美元有所加大。虽然亏损数字与华尔街分析师此前的平均预期值相符,但公司无法实现正营收,净亏损继续扩大,仍让投资者对其增长前景失去信心。
值得注意的是,库拉公司目前没有上市产品,只有一款临床阶段的抗癌药物tipifarnib,用于治疗实体瘤和血液癌。公司能否顺利推进药物研发并实现营收,将直接决定其未来盈利能力。第三季度的亏损加大,凸显了公司短期内仍将持续高烧钱的状态。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.